Comparative Pharmacology
Head-to-head clinical analysis: ESOMEPRAZOLE MAGNESIUM versus PREVACID NAPRAPAC 250 COPACKAGED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESOMEPRAZOLE MAGNESIUM versus PREVACID NAPRAPAC 250 COPACKAGED.
ESOMEPRAZOLE MAGNESIUM vs PREVACID NAPRAPAC 250 (COPACKAGED)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Esomeprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H+/K+ ATPase at the secretory surface of gastric parietal cells.
Lansoprazole: Proton pump inhibitor that irreversibly inhibits H+/K+ ATPase in gastric parietal cells, reducing gastric acid secretion. Naproxen: Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis.
20-40 mg orally once daily; for erosive esophagitis, 40 mg once daily for 4-8 weeks. IV: 20-40 mg once daily over 10-30 minutes.
Lansoprazole 15 mg plus naproxen 250 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 1–1.5 hours in healthy individuals, but may be prolonged to 2–3 hours in poor metabolizers (CYP2C19) or patients with hepatic impairment. The effect on gastric acid secretion persists for 24 hours due to irreversible binding to proton pumps.
Naproxen: 12-17 hours (terminal), allows twice-daily dosing. Lansoprazole: 1-2 hours (terminal), but acid suppression persists due to accumulation in parietal cells.
Approximately 80% of a dose is excreted as metabolites in urine, with the remainder (about 20%) eliminated in feces via biliary excretion. Less than 1% is excreted unchanged in urine.
Naproxen: Renal (95% as unchanged drug and metabolites, primarily 6-O-desmethyl naproxen), fecal (<5%). Lansoprazole: Renal (20% as metabolites), fecal (80% as metabolites).
Category A/B
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor/NSAID Combination